Payment overview · 2025
General Payments
$192,878.66
128 reported records · 14 companies
Healthcare provider profile · identity verified
Ruth Ann Vleugels, MD
Allopathic & Osteopathic Physicians|Dermatology · BOSTON, MA · NPI 1124154554
Verified facts
What the public records show
CMS Open Payments records show Ruth Ann Vleugels, MD received $192,878.66 in general payments during 2025 across 128 reported records.
Eli Lilly and Company accounted for 26.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Panzyga, Rinvoq.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RINVOQ as an associated drug or biological on 279238 records involving 34343 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Rinvoq by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PANZYGA as an associated drug or biological on 8346 records involving 3334 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Panzyga by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XELJANZ as an associated drug or biological on 32588 records involving 8614 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Xeljanz by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Eli Lilly and Company | Unresolved — no canonical attribution shown | $51,061.92 | 26.5% | 35 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $46,127.96 | 23.9% | 19 | 2025 |
| AstraZeneca UK Limited | Unresolved — no canonical attribution shown | $24,688.13 | 12.8% | 18 | 2025 |
| Boehringer Ingelheim International GmbH | Unresolved — no canonical attribution shown | $16,357.07 | 8.5% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $15,489.33 | 8.0% | 12 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $13,750.07 | 7.1% | 17 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $13,204.99 | 6.8% | 15 | 2025 |
| Janssen Scientific Affairs, LLC | Unresolved — no canonical attribution shown | $5,860.00 | 3.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $2,325.00 | 1.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $2,160.00 | 1.1% | 2 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $1,500.00 | 0.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $268.50 | 0.1% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $47.50 | 0.0% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $38.19 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $121,361.47 | 35 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $45,375.00 | 9 |
| Travel and Lodging | $23,417.18 | 36 |
| Food and Beverage | $2,725.01 | 48 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OLUMIANT Normalized: olumiant |
Drug | Eli Lilly and Company | $25,060.64 | 10 | 2025 |
Source payment records
|
|||||
| SAPHNELO Normalized: saphnelo |
Biological | AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited | $24,956.63 | 19 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc., Janssen Scientific Affairs, LLC | $19,064.99 | 16 | 2025 |
Source payment records
|
|||||
| EBGLYSS Normalized: ebglyss |
Drug | Eli Lilly and Company, Lilly USA, LLC | $15,700.74 | 9 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $4,220.33 | 6 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $2,160.00 | 2 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $1,500.00 | 1 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $950.03 | 2 | 2025 |
Source payment records
|
|||||
| Sotyktu Normalized: sotyktu |
Drug | E.R. Squibb & Sons, L.L.C. | $411.18 | 5 | 2025 |
Source payment records
|
|||||
| COSENTYX Normalized: cosentyx |
Drug | Novartis Pharmaceuticals Corporation | $47.50 | 2 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $38.19 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| PANZYGA panzyga |
2025 | Panzyga | 2024 | 58 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| RINVOQ rinvoq |
2025 | Rinvoq | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | RINVOQ open payments reported associated product |
CMS Open Payments — General Payments 279238 supporting records · 34343 recipient NPIs · example record 1201352600 |
Rinvoq · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PANZYGA open payments reported associated product |
CMS Open Payments — General Payments 8346 supporting records · 3334 recipient NPIs · example record 1228795271 |
Panzyga · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | XELJANZ open payments reported associated product |
CMS Open Payments — General Payments 32588 supporting records · 8614 recipient NPIs · example record 1228794176 |
Xeljanz · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Octagam | Immun Globg(Igg)/Malt/Iga Ov50 | 97 | suppressed |
| Methotrexate | Methotrexate Sodium | 89 | 24 |
| Dupixent Syringe | Dupilumab | 75 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 70 | 21 |
| Panzyga | Immun Glob G(Igg)-Ifas/Glycine | 58 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 50 | 12 |
| Dupixent Pen | Dupilumab | 45 | suppressed |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 43 | suppressed |
| Ketoconazole | Ketoconazole | 43 | 15 |
| Minoxidil | Minoxidil | 43 | 13 |
| Clobetasol Propionate | Clobetasol Propionate | 38 | 29 |
| Pentoxifylline | Pentoxifylline | 38 | 11 |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 34 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 25 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 31 | 15 |
| Rinvoq | Upadacitinib | 30 | suppressed |
| Xeljanz | Tofacitinib Citrate | 27 | suppressed |
| Sodium Chloride | Sodium Chloride 0.45 % | 18 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Mycophenolic Acid | Mycophenolate Sodium | 16 | suppressed |
| Prednisone | Prednisone | 15 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Dapsone | Dapsone | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Gabapentin | Gabapentin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $192,878.66 · 128 records | Eli Lilly and Company | Bimzelx, COSENTYX, DUPIXENT, EBGLYSS, OLUMIANT, PANZYGA, RINVOQ, SAPHNELO, SKYRIZI, Sotyktu, TREMFYA | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Panzyga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error